Professor CHAN Ho Yin Edwin

Address

(Office): Rm 509B, Mong Man Wai Building
(Lab): Rm 509A, Mong Man Wai Building

People CHY3
 

Phone

(Office): (852) 3943 4021
(Lab): (852) 3943 8032

Fax (852) 2603 7732
Email This email address is being protected from spambots. You need JavaScript enabled to view it.
Web

i. http://www.bch.cuhk.edu.hk/LDR/LDR_news.html
ii. http://www.bch.cuhk.edu.hk/LDR/LDR_publication.aspiii.
iii. http://scholars.croucher.org.hk/scholars/chan-ho-yin-edwin

Education

1999 Ph.D. University of Cambridge
1995 B.Sc. The Chinese University of Hong Kong


Positions

  • Professor, School of Life Sciences
  • Director, Biochemistry Programme
  • Deputy Director, Natural Sciences Programme, Science Faculty
  • Director, Laboratory of Drosophila Research
  • Warden, Postgraduate Halls


Research Interests
 

  • Human disease modelling
  • Cellular, genetic and biochemical analyses of RNA and protein toxicity in neurological diseases
  • Therapeutic intervention of neurological diseases


Representative Publications

  • Chen, Z.S., Ou, M., Taylor, S., Dafinca, R., Peng, S.I., Talbot, K.* and Chan, H.Y.E.* (2023) Mutant GGGGCC RNA prevents YY1 from binding to Fuzzy promoter which stimulate Wnt/b-catenin pathway in C9ALS/FTD. Nat. Commun. 14(1):8420
  • An, Y., Chen, Z.S., Chan, H.Y.E.* and Ngo, J.C.K.* (2022) Molecular insights into the interaction of CAG trinucleotide RNA repeats with nucleolin and its implication in polyglutamine diseases. Nucl. Acids Res. 50(13), 7655-7668.
  • Peng, S.I., Leong, L.I., Sun, J.K., Chen, Z.S., Chow, H.M. and Chan, H.Y.E.* (2022) A peptide inhibitor that rescues polyglutamine-induced synaptic defects and cell death through suppressing RNA and protein toxicities. Mol. Ther. Nucleic Acids 29, 102-115.
  • Peng, S., Guo, P., Lin, X., An, Y., Sze, K.H., Lau, M.H.Y., Chen, Z.S., Wang, Q., Li, W., Sun, J.K., Ma, S.Y., Chan, T.F., Lau, K.F., Ngo, J.C.K., Kwan, K.M., Wong, C.H., Lam, S.L., Zimmerman, S.C., Tuccinardi, T., Zuo, Z., Au Yeung, H.Y., Chow, H.M. and Chan, H.Y.E.* (2021) CAG RNAs induce DNA damage and apoptosis by silencing NUDT16 expression in polyglutamine degeneration. Proc. Natl. Acad. Sci. USA. 118(19) e2022940118
  • Chen, Z.S., Huang, X., Talbot, K. and Chan, H.Y.E.* (2021) A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3. Cell Death Dis. 12(2):136
  • Zhang, Q., An, Y., Chen, Z.S., Koon, A.C., Lau, K.F., Ngo, J.C.* and Chan, H.Y.E.* (2019) A peptidylic inhibitor for neutralizing r(GGGGCC)exp-associated neurodegeneration in C9ORF72-associated amyotrophic lateral sclerosis and frontotemporal dementia. Mol. Ther. Nucleic Acids 16, 172-185.
  • Chen, Z.S., Li, L., Peng, S., Chen, F.M., Zhang, Q., An, Y., Lin, X., Li, W., Chan, T.F., Lau, K.F., Ngo, J.C., Wong, W.T., Kwan, K.M. and Chan, H.Y.E.* (2018) Planar cell polarity gene Fuz triggers apoptosis in neurodegenerative diseases. EMBO Rep. 19, e45419
  • Tsoi, H., Yu, A.C., Chen, Z.S., Ng, N.K., Chan, A.Y., Yuen, L.Y., Abrigo, J.M., Tsang, S.Y., Tsui, S.K., Tong, T.M., Lo, I.F., Lam, S.T., Mok, V.C, Wong, L.K., Ngo, C.K., Lau, K.F., Chan, T.F.* and Chan, H.Y.E.* (2014) A novel missense mutation in CCDC88C activates the JNK pathway and causes a dominant form of spinocerebellar ataxia. J. Med. Genet. 51, 590-595.
  • Lu, J.H., Tan, J.Q., Durairajan, S.S., Liu, L.F., Zhang, Z.H., Ma, L., Shen, H.M., Chan, H.Y.E.* and Li, M.* (2012) Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy. Autophagy 8, 98-108.
  • Tsoi, H., Lau, C.K., Tsang, S.Y., Lau, K.F. and Chan, H.Y.E.* (2012) CAG expansion induces nucleolar stress in polyglutamine diseases. Proc. Natl. Acad. Sci. USA. 109, 13428-13433. F1000-r1


Research Grants

  • 2024-2026, Research Grants Council (RGC) GRF Grant, Investigating the heterozygous mutational effect of the CCDC88C gene on causing spinocerebellar ataxia, $1,592,000
  • 2021-2022, Research Grants Council (RGC) GRF Grant, The role of adhesion molecule FasII/NCAM in synaptic dysfunction and neurodegeneration in myotonic dystrophy type I, $892,655
  • 2020-2022, Research Grants Council (RGC) GRF Grant, How can we handle DNA damage induced by toxic RNAs?, $1,097,419
  • 2019-2020, Research Grants Council (RGC) GRF Grant, Investigating the role of PAPD5 and its target microRNAs in RNA toxicity of polyglutamine diseases., $677,160
  • 2016-2017, Research Grants Council (RGC) GRF Grant, Dissecting the regulatory mechanism of ubiquitin E3 ligase activity and understanding the importance of such regulation in polyglutamine pathogenesis., $768,202
  • 2015-2019, The French National Research Agency (ANR)/Research Grants Council (RGC) Joint Research Scheme, Refining the bioactivity of P42, a hit therapeutic peptide, and developing a combined therapeutic peptide approach for treating Huntington’s Disease., $2,540,083
  • 2015-2017, Research Grants Council (RGC) GRF Grant, Characterization of a novel pathogenic pathway of Huntington's Disease., $877,717
  • 2014-2017, Research Grants Council (RGC) CRF Grant, Targeting RNA and protein toxicities of polyglutamine diseases using peptidylic inhibitors., $7,044,220
  • 2014-2016, Research Grants Council (RGC) GRF Grant, Characterization of a novel type of protein nuclear export signal in polyalanine expansion disease proteins., $866,032
  • 2013-2015, Health and Medical Research Fund (HMRF) Grant, An inhibitory peptide approach to simultaneously target RNA and protein toxicities in polyglutamine degeneration., $999,908
  • 2013-2015, Research Grants Council (RGC) GRF Grant, The role of nucleolin in CAG trinucleotide repeat-mediated RNA toxicity., $790,000
  • 2009-2012, Research Grants Council (RGC) GRF Grant, Probing the nuclear transport role of the mutant polyglutamine domain in neurodegeneration., $929,247
  • 2009-2011, Research Fund for the Control of Infectious Diseases Research (RFCID) Grant, Investigating the involvement of P13K/PDK-1/Akt pathways and Notch signals in SARS-CoV Membrane-induced apoptosis., $741,448
  • 2009-2010, Cure Huntington’s Disease Initiative Foundation Early Discovery Initiative Fund, USA, Using the 3B5H10 Monoclonal Antibody to Investigate Huntingtin Oligomer and Toxicity in vivo., $444,149
  • 2004-2007, Research Grants Council (RGC) Earmarked Grant, Nucleocytoplasmic transport and polyglutamine toxicity: A cellular genetic study., $1,265,677
  • 2004-2006, Research Fund for the Control of Infectious Diseases Research (RFCID) Grant, Molecular and Genetic Characterization of the SARS Coronavirus Auxiliary Protein X1 in Drosophila., $675,144
  • 2003-2007, Research Grants Council (RGC) Earmarked Grant, Genetic and proteomic studies of chaperone-mediated suppression of polyglutamine toxicity in Drosophila., $1,203,000

Patents

  • Chan, H. Y. E.; Ngo, J. C.; Wong, C.; Zhang, Q.; Peng, S. Small molecule inhibitors targeting CAG-repeat RNA toxicity in polyglutamine diseases. U.S. Patent US 10,143,666, Dec 4, 2018
  • Chan, H.Y.E.; Ngo, J.C.; Zhang, Q. Peptidylic inhibitors targeting C9ORF72 hexanucleotide repeat-mediated neurodegeneration. U.S. Patent US-2018-0214515-A1, August 2, 2018
  • Chan, H.Y.E.; Ngo, J.C.; Zhang, Q. Peptidylic inhibitor targeting CAG-repeat RNA toxicity in polyglutamine diseases. U.S. Patent US-2017-0233442-A1, August 17, 2017
  • Chan, H.Y.E.; Jensen, K.J.; Ngo, J.C.; Sorensen, K.K.; Zhang, Q.; Zuo, Z. P3 Peptidylic inhibitors for treating CAG-repeat RNA toxicity in polyglutamine diseases. U.S. Patent 62/465,513, March 10, 2017
  • Chan, H. Y. E.; Tsoi, H.; Ngo, J. C.; Lau, K. F. Therapeutic approach for polyglutamine degeneration. U.S. Patent US 9,297,798, March 29, 2016


Awards

  • 2014 Churchill College Visiting By-Fellowship, University of Cambridge, UK
  • 2011 Genetics Society of China Thirteenth Ju-Chi Li Animal Genetics Prize (第十三届李汝祺动物遗传学奖)
  • The 2009 Young Researcher Award, The Chinese University of Hong Kong
  • The 2009 Faculty Exemplary Teaching Award, Faculty of Science, The Chinese University of Hong Kong

 
Professional Activities

  • Council Member, Genetics Society of China
  • Member, Biology and Medicine Panel (Joint Research Scheme), Research Grants Council (RGC) of Hong Kong
  • Member, Ataxia Global Initiative, a worldwide multi-stakeholder research platform to systematically enhance trial-readiness in degenerative ataxias
  • Associate Editor, Frontiers in Neurodegeneration
  • Founding member, The Hong Kong Young Academy of Sciences
  • Topic Editor, Frontiers in Cellular Neuroscience
  • Editoral Board, Advances in Alzheimer's Disease
  • Editoral Board, RNA & DISEASE
  • Member, Scientific Advisory Committee, Society for Research on the Cerebellum


Others

  • Session Chair (Models and Mechanism 1), Pan-Asian Consortium for Treatment and Research in ALS (PACTALS), Malaysia, 2023
  • Co-Founder, Rare Power Limited
  • Member, Charter of the Ataxia Global Initiative working group, Ataxia Global Initiative
  • Member, Medical Advisory Board, Advancing CTNNB1 Cures and Treatments Inc.
  • Member, Academic Committee of Asia Pacific Drosophila Neuroscience Conference, Academia Sinica, Taiwan, 2019
  • Organizer, Inaugural Asia-Pacific Drosophila Neurobiology Conference, Wuhan, China, 2017
  • Session Chair (Drosophila models for human diseases), 2nd Asia-Pacific Drosophila Research Conference, Seoul, Korea, 2013
  • Chairperson, Scientific and Medical Advisory Committee, Hong Kong Spinocerebellar Ataxia Association, 2012 – present

 

Current Academic/Research Positions of Lab Alumni

  • Dr. An Ying, Research Assistant Professor, School of Life Sciences, Southern University of Science and Technology, China
  • Dr. Chan Kam Leung, Lecturer, School of Chinese Medicine, CUHK
  • Dr. Chan Priscilla, Director of Research & Development (Healthcare), Nano and Advanced Materials Institute Limited, HK
  • Dr. Chen Stephen, Postdoc Fellow, University of Oxford, UK
  • Dr. Cheng Tat Cheung, CryoEM scientist, University of Gottingen, Germany
  • Dr. Chuck Chi Pang, Research Scientist, Polytide Technology Inc., Canada
  • Dr. Choi Ching Gee, Postdoc Fellow, HKU
  • Professor Choi Jonathan, Associate Professor, Department of Biomedical Engineering, CUHK
  • Dr. Huen Macy, Manager, Technology Transfer and Commercialization, Intellectual Property Management, Hong Kong Polytechnic University
  • Dr. Koon Alex Chun, Senior Lecturer, School of Life Sciences, CUHK
  • Dr. Law Carman, Postdoc Fellow, City University of Hong Kong
  • Dr. Li Li, Postdoc Fellow, College of Physics Science and Technology, Shenzhen University
  • Dr. Ng Nelson, Postdoc Fellow, HKU
  • Dr. Peng Isaac, Project Scientist, UC Irvine, USA
  • Professor Wong Siu Lun Alan, Associate Professor, School of Biomedical Sciences, HKU
  • Dr. Wu Chi Chung, Junior Group Leader, European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University
  • Dr. Zhang Qian, Clinical Trial Manager, Medpace, Bavaria, Germany